| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cure for HIV: how would we know?
|
Zerbato, Jennifer M
|
|
|
|
5 |
p. e304-e306
|
artikel
|
| 2 |
All the viral loads we cannot see
|
Phillips, Tamsin K
|
|
|
|
5 |
p. e246-e247
|
artikel
|
| 3 |
ART coverage in Rwanda: successes and remaining challenges
|
Barnabas, Ruanne V
|
|
2015
|
|
5 |
p. e176-e177
nvt p.
|
artikel
|
| 4 |
A story of bad blood, corruption, and politics
|
Burki, Talha
|
|
|
|
5 |
p. e321
|
artikel
|
| 5 |
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey
|
Gaolathe, Tendani
|
|
2016
|
|
5 |
p. e221-e230
nvt p.
|
artikel
|
| 6 |
Broadly neutralising antibodies in post-treatment control
|
de Bree, Godelieve J
|
|
|
|
5 |
p. e271-e272
|
artikel
|
| 7 |
Can COVID-19 changes reduce stigma in African HIV clinics?
|
Lofgren, Sarah M
|
|
|
|
5 |
p. e304-e305
|
artikel
|
| 8 |
Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action
|
Penazzato, Martina
|
|
2018
|
|
5 |
p. e259-e264
|
artikel
|
| 9 |
Children and young women in eastern and southern Africa are key to meeting 2030 HIV targets: time to accelerate action
|
Govender, Kaymarlin
|
|
|
|
5 |
p. e343-e350
|
artikel
|
| 10 |
Cities central to HIV response for people who use drugs
|
Tinasti, Khalid
|
|
2016
|
|
5 |
p. e197-e199
nvt p.
|
artikel
|
| 11 |
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study
|
Phillips, Andrew N
|
|
|
|
5 |
p. e353-e362
|
artikel
|
| 12 |
Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants: a systematic review of modelling studies
|
le Roux, Stanzi M
|
|
|
|
5 |
p. e320-e331
|
artikel
|
| 13 |
COVID-19 in patients with HIV: clinical case series
|
Blanco, Jose L
|
|
|
|
5 |
p. e314-e316
|
artikel
|
| 14 |
Dean Street clinics—battling London's MSM HIV epidemic
|
Kirby, Tony
|
|
2018
|
|
5 |
p. e210
|
artikel
|
| 15 |
Definitions of implementation science in HIV/AIDS
|
Odeny, Thomas A
|
|
2015
|
|
5 |
p. e178-e180
nvt p.
|
artikel
|
| 16 |
Documenting the UK's 40-year battle with HIV/AIDS
|
Burki, Talha
|
|
|
|
5 |
p. e308
|
artikel
|
| 17 |
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
|
Waalewijn, Hylke
|
|
|
|
5 |
p. e341-e352
|
artikel
|
| 18 |
Dolutegravir intensification and HIV persistence: 3 + 1 = 3
|
Henrich, Timothy J
|
|
2018
|
|
5 |
p. e201-e202
|
artikel
|
| 19 |
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial
|
Kintu, Kenneth
|
|
|
|
5 |
p. e332-e339
|
artikel
|
| 20 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
|
Molina, Jean-Michel
|
|
2018
|
|
5 |
p. e211-e220
|
artikel
|
| 21 |
Doubts hang over PEPFAR finances
|
The Lancet HIV,
|
|
2017
|
|
5 |
p. e189-
1 p.
|
artikel
|
| 22 |
Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?
|
Shiau, Stephanie
|
|
2018
|
|
5 |
p. e250-e258
|
artikel
|
| 23 |
Economics of point-of-care infant HIV tests
|
Ochieng, Walter O
|
|
|
|
5 |
p. e278-e279
|
artikel
|
| 24 |
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
|
Mallewa, Jane
|
|
2018
|
|
5 |
p. e231-e240
|
artikel
|
| 25 |
Empowering women: addressing HIV vertical transmission in the Philippines
|
Basilio, Patricia Anne S
|
|
|
|
5 |
p. e306
|
artikel
|
| 26 |
Enrolling pregnant women with HIV into clinical trials
|
Orkin, Chloe
|
|
|
|
5 |
p. e302-e303
|
artikel
|
| 27 |
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study
|
Smiley, Casey L
|
|
|
|
5 |
p. e266-e273
|
artikel
|
| 28 |
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report
|
Gupta, Ravindra Kumar
|
|
|
|
5 |
p. e340-e347
|
artikel
|
| 29 |
Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations
|
Vannakit, Ravipa
|
|
|
|
5 |
p. e366-e372
|
artikel
|
| 30 |
From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa
|
Haber, Noah
|
|
2017
|
|
5 |
p. e223-e230
nvt p.
|
artikel
|
| 31 |
Group support psychotherapy for depression treatment in people with HIV/AIDS in northern Uganda: a single-centre randomised controlled trial
|
Nakimuli-Mpungu, Etheldreda
|
|
2015
|
|
5 |
p. e190-e199
nvt p.
|
artikel
|
| 32 |
Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial
|
Blanche, Stéphane
|
|
|
|
5 |
p. e307-e314
|
artikel
|
| 33 |
Highlights of the 25th CROI
|
Hayward, Peter
|
|
2018
|
|
5 |
p. e209
|
artikel
|
| 34 |
HIV and COVID-19: juxtaposition of two pandemics
|
Nkengasong, John
|
|
|
|
5 |
p. e300-e301
|
artikel
|
| 35 |
HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study
|
Smith, Adrian D
|
|
|
|
5 |
p. e274-e283
|
artikel
|
| 36 |
HIV care continuum in Rwanda: a cross-sectional analysis of the national programme
|
Nsanzimana, Sabin
|
|
2015
|
|
5 |
p. e208-e215
nvt p.
|
artikel
|
| 37 |
HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study
|
Wirtz, Andrea L
|
|
|
|
5 |
p. e308-e319
|
artikel
|
| 38 |
HIV incidence and scale-up of prevention in western Kenya
|
Sewankambo, Nelson K
|
|
2018
|
|
5 |
p. e204-e205
|
artikel
|
| 39 |
HIV incidence in western Kenya during scale-up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis
|
Borgdorff, Martien W
|
|
2018
|
|
5 |
p. e241-e249
|
artikel
|
| 40 |
HIV in the Amazon's indigenous populations
|
Daniels, Joe Parkin
|
|
|
|
5 |
p. e253-e254
|
artikel
|
| 41 |
HIV prevention resources: time to move toward affordability
|
Kimmel, April D
|
|
2017
|
|
5 |
p. e191-e193
nvt p.
|
artikel
|
| 42 |
HIV-related stigma among health-care workers in the MENA region
|
Ballouz, Tala
|
|
|
|
5 |
p. e311-e313
|
artikel
|
| 43 |
How to motivate hard-to-reach men to accept circumcision
|
Serwadda, David
|
|
2015
|
|
5 |
p. e170-e171
nvt p.
|
artikel
|
| 44 |
How universal does universal test and treat have to be?
|
Baggaley, Rebecca F
|
|
|
|
5 |
p. e306-e308
|
artikel
|
| 45 |
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
|
Madhi, Shabir A
|
|
|
|
5 |
p. e309-e322
|
artikel
|
| 46 |
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
|
Dorward, Jienchi
|
|
|
|
5 |
p. e284-e294
|
artikel
|
| 47 |
Indiana HIV outbreak should inspire long-term changes
|
The Lancet HIV,
|
|
2015
|
|
5 |
p. e169-
1 p.
|
artikel
|
| 48 |
INPACVIH: tackling HIV in Peru's indigenous communities
|
Daniels, Joe Parkin
|
|
|
|
5 |
p. e255
|
artikel
|
| 49 |
Integrated HIV prevention and care for key populations
|
Oldenburg, Catherine E
|
|
|
|
5 |
p. e270-e271
|
artikel
|
| 50 |
Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial
|
Solomon, Sunil S
|
|
|
|
5 |
p. e283-e296
|
artikel
|
| 51 |
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial
|
Aliyu, Muktar H
|
|
2016
|
|
5 |
p. e202-e211
nvt p.
|
artikel
|
| 52 |
Invest in HIV now to reap future rewards
|
The Lancet HIV,
|
|
|
|
5 |
p. e273
|
artikel
|
| 53 |
Is 90-90-90 achievable?
|
Rutherford, George W
|
|
2017
|
|
5 |
p. e193-e194
nvt p.
|
artikel
|
| 54 |
Is increasing pretreatment HIV drug resistance a real menace or minor detail?
|
Inzaule, Seth C
|
|
|
|
5 |
p. e316-e317
|
artikel
|
| 55 |
Is increasing pretreatment HIV drug resistance a real menace or minor detail? – Authors' reply
|
Chung, Michael H
|
|
|
|
5 |
p. e317-e318
|
artikel
|
| 56 |
Is the UNAIDS target sufficient for HIV control in Botswana?
|
Karim, Salim Abdool
|
|
2016
|
|
5 |
p. e195-e196
nvt p.
|
artikel
|
| 57 |
It was the best of times, it was the worst of times…
|
Martin, Colin
|
|
|
|
5 |
p. e282-e283
|
artikel
|
| 58 |
Legal reforms signal a change in India's HIV response
|
Cousins, Sophie
|
|
|
|
5 |
p. e279-e280
|
artikel
|
| 59 |
Levelling up HIV testing for the endgame
|
The Lancet HIV,
|
|
|
|
5 |
p. e299
|
artikel
|
| 60 |
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|
Trickey, Adam
|
|
|
|
5 |
p. e295-e307
|
artikel
|
| 61 |
Life-expectancy with HIV in Latin America and the Caribbean
|
Coelho, Lara E
|
|
|
|
5 |
p. e247-e248
|
artikel
|
| 62 |
Linkage to care: a step on the path, but not the destination
|
Sabapathy, Kalpana
|
|
2016
|
|
5 |
p. e193-e194
nvt p.
|
artikel
|
| 63 |
Living longer with HIV: gains for some but not for all
|
Klein, Marina B
|
|
|
|
5 |
p. e275-e276
|
artikel
|
| 64 |
Long-acting antiretrovirals and HIV treatment adherence
|
Nachega, Jean B
|
|
|
|
5 |
p. e332-e342
|
artikel
|
| 65 |
Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study
|
Lyatuu, Goodluck W
|
|
|
|
5 |
p. e256-e265
|
artikel
|
| 66 |
Maintaining HIV care during the COVID-19 pandemic
|
Jiang, Hongbo
|
|
|
|
5 |
p. e308-e309
|
artikel
|
| 67 |
Matching love and HIV in India
|
Burki, Talha
|
|
|
|
5 |
p. e282
|
artikel
|
| 68 |
Moving forward with dolutegravir in children weighing less than 20 kg
|
Rabie, Helena
|
|
|
|
5 |
p. e301-e302
|
artikel
|
| 69 |
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions
|
Moore, Cecilia L
|
|
|
|
5 |
p. e334-e340
|
artikel
|
| 70 |
Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study
|
Poon, Art F Y
|
|
2016
|
|
5 |
p. e231-e238
nvt p.
|
artikel
|
| 71 |
Need for transgender-specific data from Africa and elsewhere
|
Chakrapani, Venkatesan
|
|
|
|
5 |
p. e249-e250
|
artikel
|
| 72 |
NHS England should reconsider PrEP decision
|
The Lancet HIV,
|
|
2016
|
|
5 |
p. e191-
1 p.
|
artikel
|
| 73 |
Nutritional support to reduce mortality in patients with HIV?
|
PrayGod, George
|
|
2018
|
|
5 |
p. e202-e204
|
artikel
|
| 74 |
Opportunities and limits for dolutegravir in late pregnancy
|
Kufa, Tendesayi
|
|
|
|
5 |
p. e303-e304
|
artikel
|
| 75 |
Optimising HIV antiretrovirals for mothers and infants
|
Powis, Kathleen M
|
|
|
|
5 |
p. e272-e273
|
artikel
|
| 76 |
Overview of SARS-CoV-2 infection in adults living with HIV
|
Ambrosioni, Juan
|
|
|
|
5 |
p. e294-e305
|
artikel
|
| 77 |
Pakistan continues to battle paediatric HIV outbreak
|
Burki, Talha
|
|
|
|
5 |
p. e307
|
artikel
|
| 78 |
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
|
Ruel, Theodore D
|
|
|
|
5 |
p. e332-e340
|
artikel
|
| 79 |
Phylogenetic inference for the study of within-host HIV-1 dynamics and persistence on antiretroviral therapy
|
Capoferri, Adam A
|
|
|
|
5 |
p. e325-e333
|
artikel
|
| 80 |
Pregnancy outcomes for new ART regimens
|
Lamorde, Mohammed
|
|
|
|
5 |
p. e274-e275
|
artikel
|
| 81 |
PrEP adherence among trans women in Brazil—access needed for this key population
|
Wilson, Erin C
|
|
2016
|
|
5 |
p. e200-
1 p.
|
artikel
|
| 82 |
PrEP adherence among trans women in Brazil—access needed for this key population – Authors' reply
|
Sevelius, Jae
|
|
2016
|
|
5 |
p. e200-e201
nvt p.
|
artikel
|
| 83 |
PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study
|
Cremin, Ide
|
|
2017
|
|
5 |
p. e214-e222
nvt p.
|
artikel
|
| 84 |
Prioritisation of subgroups for immediate antiretroviral therapy
|
Wu, Zunyou
|
|
2018
|
|
5 |
p. e206
|
artikel
|
| 85 |
Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply
|
Molina, Jean-Michel
|
|
2018
|
|
5 |
p. e206
|
artikel
|
| 86 |
Psychological therapy to improve HIV care and reduce stigma
|
Katz, Ingrid T
|
|
2015
|
|
5 |
p. e172-e173
nvt p.
|
artikel
|
| 87 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
|
João, Esaú C
|
|
|
|
5 |
p. e322-e331
|
artikel
|
| 88 |
Reaching out to readers
|
The Lancet HIV,
|
|
2015
|
|
5 |
p. e169-
1 p.
|
artikel
|
| 89 |
Realising the potential of risk-informed PrEP
|
Schaefer, Robin
|
|
|
|
5 |
p. e302-e304
|
artikel
|
| 90 |
Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
|
McAuley, Andrew
|
|
|
|
5 |
p. e315-e324
|
artikel
|
| 91 |
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
|
Crowell, Trevor A
|
|
|
|
5 |
p. e297-e306
|
artikel
|
| 92 |
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
|
Netto, Lucas C
|
|
|
|
5 |
p. e323-e331
|
artikel
|
| 93 |
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?
|
Schmidt, Heather-Marie A
|
|
|
|
5 |
p. e363-e366
|
artikel
|
| 94 |
Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study
|
Zhang, Lei
|
|
2015
|
|
5 |
p. e200-e207
nvt p.
|
artikel
|
| 95 |
Social determinants of transgender women's health
|
Cáceres, Carlos F
|
|
|
|
5 |
p. e276-e278
|
artikel
|
| 96 |
Social media helping younger adults combat HIV stigma
|
Ligami, Christabel
|
|
|
|
5 |
p. e280-e281
|
artikel
|
| 97 |
Strengthening measurement and performance of HIV prevention programmes
|
Holmes, Charles B
|
|
|
|
5 |
p. e306-e310
|
artikel
|
| 98 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
|
DeJesus, Edwin
|
|
2017
|
|
5 |
p. e205-e213
nvt p.
|
artikel
|
| 99 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
|
Orkin, Chloe
|
|
2017
|
|
5 |
p. e195-e204
nvt p.
|
artikel
|
| 100 |
Tenofovir prodrugs: similar but not the same
|
Bruggemans, Anne
|
|
2017
|
|
5 |
p. e190-e191
nvt p.
|
artikel
|
| 101 |
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial
|
Rasmussen, Thomas A
|
|
2018
|
|
5 |
p. e221-e230
|
artikel
|
| 102 |
The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study
|
Akullian, Adam
|
|
|
|
5 |
p. e348-e358
|
artikel
|
| 103 |
The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV
|
Palma, Paolo
|
|
|
|
5 |
p. e359-e365
|
artikel
|
| 104 |
The link between modelling and doing
|
Johns, Benjamin
|
|
2015
|
|
5 |
p. e174-e175
nvt p.
|
artikel
|
| 105 |
The role of testing in HIV prevention
|
The Lancet HIV,
|
|
2017
|
|
5 |
p. e189-
1 p.
|
artikel
|
| 106 |
The Spear and Shield intervention to increase the availability and acceptability of voluntary medical male circumcision in Zambia: a cluster randomised controlled trial
|
Weiss, Stephen M
|
|
2015
|
|
5 |
p. e181-e189
nvt p.
|
artikel
|
| 107 |
The war on drugs is incompatible with the fight against HIV
|
The Lancet HIV,
|
|
|
|
5 |
p. e269
|
artikel
|
| 108 |
Three lessons for the COVID-19 response from pandemic HIV
|
Hargreaves, James
|
|
|
|
5 |
p. e309-e311
|
artikel
|
| 109 |
Towards no missed opportunities: the experience of 56 Dean Street
|
Gregson, Sam
|
|
|
|
5 |
p. e251-e252
|
artikel
|
| 110 |
Translating phylogeny into action for HIV surveillance
|
Gardy, Jennifer L
|
|
2016
|
|
5 |
p. e196-e197
nvt p.
|
artikel
|
| 111 |
Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data
|
Giguère, Katia
|
|
|
|
5 |
p. e284-e293
|
artikel
|
| 112 |
Tuberculosis and HIV responses threatened by COVID-19
|
Adepoju, Paul
|
|
|
|
5 |
p. e319-e320
|
artikel
|
| 113 |
UK sexual health services struggle with public health cuts
|
Kirby, Tony
|
|
2018
|
|
5 |
p. e207-e208
|
artikel
|
| 114 |
UNAIDS strategy aligns HIV priorities with development goals
|
The Lancet HIV,
|
|
|
|
5 |
p. e245
|
artikel
|
| 115 |
Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda
|
Barnabas, Ruanne V
|
|
2016
|
|
5 |
p. e212-e220
nvt p.
|
artikel
|
| 116 |
Using PMTCT to raise overall health and development
|
Coovadia, Hoosen
|
|
2016
|
|
5 |
p. e192-e193
nvt p.
|
artikel
|
| 117 |
When pandemics collide
|
The Lancet HIV,
|
|
|
|
5 |
p. e301
|
artikel
|
| 118 |
Why do HIV outbreaks re-emerge among people who inject drugs?
|
Sypsa, Vana
|
|
|
|
5 |
p. e274-e275
|
artikel
|
| 119 |
Will NNRTIs be driving forward again?
|
Calmy, Alexandra
|
|
2018
|
|
5 |
p. e200-e201
|
artikel
|
| 120 |
Will Redfield's HIV background prepare him for top CDC job?
|
The Lancet HIV,
|
|
2018
|
|
5 |
p. e199
|
artikel
|
| 121 |
Yes4Me: reaching out to India's key populations online
|
Cousins, Sophie
|
|
|
|
5 |
p. e281
|
artikel
|
| 122 |
Youth at risk of HIV: the overlooked US HIV prevention crisis
|
Guilamo-Ramos, Vincent
|
|
|
|
5 |
p. e275-e278
|
artikel
|
Tijdschrift beschrijving